Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
Sherene Loi, Stefan Michiels, Roberto Salgado, et al.
Annals of Oncology (2014) Vol. 25, Iss. 8, pp. 1544-1550
Open Access | Times Cited: 1170

Showing 1-25 of 1170 citing articles:

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Andreas D. Hartkopf, Florin‐Andrei Taran, Markus Wallwiener, et al.
Breast Care (2016) Vol. 11, Iss. 6, pp. 385-390
Open Access | Times Cited: 30388
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
Roberto Salgado, Carsten Denkert, Sandra Demaria, et al.
Annals of Oncology (2014) Vol. 26, Iss. 2, pp. 259-271
Open Access | Times Cited: 2621
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Giampaolo Bianchini, Justin M. Balko, Ingrid A. Mayer, et al.
Nature Reviews Clinical Oncology (2016) Vol. 13, Iss. 11, pp. 674-690
Open Access | Times Cited: 2383
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel, Razelle Kurzrock
Molecular Cancer Therapeutics (2015) Vol. 14, Iss. 4, pp. 847-856
Closed Access | Times Cited: 2040
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
Alan S. Coates, Eric P. Winer, Aron Goldhirsch, et al.
Annals of Oncology (2015) Vol. 26, Iss. 8, pp. 1533-1546
Open Access | Times Cited: 1685
Clinical implications of the intrinsic molecular subtypes of breast cancer
Aleix Prat, Estela Pineda, Bárbara Adamo, et al.
The Breast (2015) Vol. 24, pp. S26-S35
Closed Access | Times Cited: 1134
Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers
Carsten Denkert, Gϋnter von Minckwitz, Jan C. Brase, et al.
Journal of Clinical Oncology (2014) Vol. 33, Iss. 9, pp. 983-991
Open Access | Times Cited: 960
Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis
Peter Savas, Balaji Virassamy, Chengzhong Ye, et al.
Nature Medicine (2018) Vol. 24, Iss. 7, pp. 986-993
Closed Access | Times Cited: 840
Clinical relevance of host immunity in breast cancer: from TILs to the clinic
Peter Savas, Roberto Salgado, Carsten Denkert, et al.
Nature Reviews Clinical Oncology (2015) Vol. 13, Iss. 4, pp. 228-241
Closed Access | Times Cited: 774
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Lyndsay N. Harris, Nofisat Ismaila, Lisa M. McShane, et al.
Journal of Clinical Oncology (2016) Vol. 34, Iss. 10, pp. 1134-1150
Open Access | Times Cited: 766
Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients
Hager R. Ali, Elena Provenzano, Sarah‐Jane Dawson, et al.
Annals of Oncology (2014) Vol. 25, Iss. 8, pp. 1536-1543
Open Access | Times Cited: 702
Clinical significance of tumor-infiltrating lymphocytes in breast cancer
Sasha E. Stanton, Mary L. Disis
Journal for ImmunoTherapy of Cancer (2016) Vol. 4, Iss. 1
Open Access | Times Cited: 689
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors
Shona Hendry, Roberto Salgado, Thomas Gevaert, et al.
Advances in Anatomic Pathology (2017) Vol. 24, Iss. 6, pp. 311-335
Open Access | Times Cited: 671
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer
Leisha A. Emens, Cristina Cruz, Joseph P. Eder, et al.
JAMA Oncology (2018) Vol. 5, Iss. 1, pp. 74-74
Open Access | Times Cited: 652
Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers
Sherene Loi, Damien Drubay, Sylvia Adams, et al.
Journal of Clinical Oncology (2019) Vol. 37, Iss. 7, pp. 559-569
Open Access | Times Cited: 646
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research
Shona Hendry, Roberto Salgado, Thomas Gevaert, et al.
Advances in Anatomic Pathology (2017) Vol. 24, Iss. 5, pp. 235-251
Open Access | Times Cited: 588
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
David Miles, Joseph Gligorov, Fabrice André, et al.
Annals of Oncology (2021) Vol. 32, Iss. 8, pp. 994-1004
Open Access | Times Cited: 559
Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study
H. Raza Ali, Leon Chlon, Paul D.P. Pharoah, et al.
PLoS Medicine (2016) Vol. 13, Iss. 12, pp. e1002194-e1002194
Open Access | Times Cited: 536
Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes
Sasha E. Stanton, Sylvia Adams, Mary L. Disis
JAMA Oncology (2016) Vol. 2, Iss. 10, pp. 1354-1354
Closed Access | Times Cited: 527
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab
Roberto Salgado, Carsten Denkert, Christine Campbell, et al.
JAMA Oncology (2015) Vol. 1, Iss. 4, pp. 448-448
Open Access | Times Cited: 522
RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
Sherene Loi, Sathana Dushyanthen, Paul A. Beavis, et al.
Clinical Cancer Research (2015) Vol. 22, Iss. 6, pp. 1499-1509
Open Access | Times Cited: 486
Prognostic and predictive value of PDL1 expression in breast cancer
Renaud Sabatier, Pascal Finetti, Émilie Mamessier, et al.
Oncotarget (2014) Vol. 6, Iss. 7, pp. 5449-5464
Open Access | Times Cited: 469
Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer
K.G.K. Deepak, Rahul Kumar Vempati, Ganji Purnachandra Nagaraju, et al.
Pharmacological Research (2020) Vol. 153, pp. 104683-104683
Closed Access | Times Cited: 443
Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq
Mihriban Karaayvaz, Simona Cristea, Shawn Gillespie, et al.
Nature Communications (2018) Vol. 9, Iss. 1
Open Access | Times Cited: 405
Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer
Maria Vittoria Dieci, Nina Radosevic‐Robin, Susan Fineberg, et al.
Seminars in Cancer Biology (2017) Vol. 52, pp. 16-25
Open Access | Times Cited: 387
Page 1 - Next Page

Scroll to top